

PRESS RELEASE

QUALIBLOOD APPOINTS JULIE WINAND AS NEW CEO AND JONATHAN DOUXFILS AS CSO AND CHAIRMAN OF THE BOARD

Namur, Belgium – 08 avril 2024 – QUALIblood, a leading innovator in blood diagnostics and healthcare solutions, proudly announces the appointment of Julie Winand as the company's new Chief Executive Officer (CEO), effective March 28, 2024. Simultaneously, Professor Jonathan Douxfils, founder and previously serving as CEO, transitions to the role of Chief Scientific Officer (CSO) and Chairman of the Board.

With over a decade of combined experience in the biotech industry, Julie Winand has demonstrated exceptional leadership and proficiency in various roles, notably at Bone Therapeutics S.A. and THERAVET S.A. Her expertise will catalyze transformative initiatives, propelling the company towards greater heights of success and innovation. Her strategic vision, proven track record in driving business growth, and passion for innovation make her the ideal leader to guide QUALIblood through its next phase of development.

In his new capacity as CSO and Chairman of the Board, Professor Douxfils will continue to play a pivotal role in shaping the scientific and strategic directions of QUALIblood. His leadership and dedication have been instrumental in the company's success thus far, and his transition to these roles ensures continuity and sustained momentum for QUALIblood growth.

Commenting on the appointments, **Bernard Masereel**, former Chairman of the Board "We are thrilled to welcome Julie Winand as our new CEO and are confident in her ability to lead QUALIblood to new heights. Jonathan Douxfils has been and will continue to be a driving force behind our success, and we look forward to his continued contributions in his new roles. With their combined expertise and leadership, the company is poised to continue delivering cutting-edge solutions and driving positive impact in the healthcare industry."

Julie Winand added: "I am sincerely proud to be part of this journey and I strongly believe in the excellence of the services provided by QUALIblood. I am very thankful to be given the opportunity to join QUALIblood in this CEO role. I thank Jonathan Douxfils, the team and the board for their trust. I look forward to working with them to continue developing our growing business and offer new innovative solutions for the products of tomorrow".

About QUALIblood

Founded in 2017 as a spin-off of the University of Namur (Belgium), QUALIblood is a Contract Research Organization (CRO) offering preclinical, clinical, and biotesting services. The dedicated teams of experts are committed to delivering excellence in every aspect of the services, from meticulous **bioanalytical assessments** to comprehensive preclinical up to post market **study management**. QUALIblood stands as pioneers, leveraging cutting-edge technologies and methodologies to ensure the **highest standards of data integrity and reliability**. QUALIblood's mission is to empower pharmaceutical and biotechnology companies, academic institutions and healthcare organizations by providing them with the insights they need to advance medical research and improve patient outcomes.